Regeneron, Sanofi Say Kevzara Phase 3 U.S. Trial in Covid-19 Patients Didn't Meet Endpoints
July 02 2020 - 5:22PM
Dow Jones News
By Stephen Nakrosis
Regeneron Pharmaceuticals Inc. and Sanofi said Thursday a U.S.
Phase 3 trial of Kevzara in Covid-19 patients didn't meet primary
or key secondary endpoints.
The companies said the trial studied Kevzara, or sarilumab, in
Covid-19 patients requiring mechanical ventilation. Results showed
the trial "did not meet its primary and key secondary endpoints
when Kevzara was added to best supportive care compared to best
supportive care alone."
The companies also said the "primary analysis group included 194
patients who were critically ill with Covid-19 and were receiving
mechanical ventilation at the time of enrollment."
Based on the results, the companies said, the trial has been
stopped. Results will be submitted to a peer-reviewed publication
later this year, they added.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 02, 2020 17:07 ET (21:07 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Sep 2023 to Sep 2024